Menu
Close
Primary links
Newsroom Home
Press Releases
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
Biosimilars
Collaborations
Events & Webcasts
Sign up for Alerts
All Press Releases
Login
All Press Releases
Filter by
<Any>
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
-Year
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Search
TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
4/24/17 7:30 am EDT
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
4/24/17 7:30 am EDT
Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
4/21/17 2:00 pm EDT
Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
4/18/17 7:30 am EDT
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
4/13/17 7:00 am EDT
Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
3/28/17 7:30 am EDT
Biogen to Report First Quarter 2017 Financial Results on April 25, 2017
3/27/17 4:01 pm EDT
Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development
3/16/17 7:00 am EDT
Biogen to Present at the Cowen & Company 37th Annual Health Care Conference
2/28/17 4:01 pm EST
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
2/15/17 5:29 pm EST
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »
all Press Releases
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
4/24/17 7:30 am EDT
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
4/24/17 7:30 am EDT
Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
4/21/17 2:00 pm EDT
Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
4/18/17 7:30 am EDT
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
4/13/17 7:00 am EDT
Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
3/28/17 7:30 am EDT
Biogen to Report First Quarter 2017 Financial Results on April 25, 2017
3/27/17 4:01 pm EDT
Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development
3/16/17 7:00 am EDT
Biogen to Present at the Cowen & Company 37th Annual Health Care Conference
2/28/17 4:01 pm EST
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
2/15/17 5:29 pm EST
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »